retatrutide clinical trial obesity Another Promising Medication (Retatrutide) for Eli Lilly and Company's Retatrutide

Diarrhea rates increase with dose: 16% at 4 mg, 22% at 8 mg, and 33-34% at 12 mg

Additional lawsuits and adverse event reports have described bowel obstruction, ileus, gallbladder disease, gallstones, cyclic vomiting syndrome, and vision-related complications involving optic nerve damage and sudden vision loss

A weight-loss percentage from one study should not be casually compared with a percentage from another study as if all conditions were identical

Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials

The 28.7% body weight loss recorded in Phase 3 exceeds every other drug on the market or in testing

What Is the Chemical Makeup of Retatrutide (12 mg)